Surgery – Blood drawn and replaced or treated and returned to body – Constituent removed from blood and remainder returned to body
Patent
1994-06-03
1995-09-19
Rimell, Sam
Surgery
Blood drawn and replaced or treated and returned to body
Constituent removed from blood and remainder returned to body
514532, A61K 4700
Patent
active
054512050
ABSTRACT:
A method for facilitating autologous blood use by a patient facing a loss of blood, comprising the steps of removing and preferably storing a portion of the patient's blood, intravenously administering a biocompatible liquid in sufficient quantity to substantially maintain the patient's hemodynamic stability, wherein the liquid comprises an effective oxygen-delivery enhancing amount of a biocompatible synthetic oxygen carrier, after which the patient undergoes a loss of blood, and then readministering blood to the patient, preferably the stored blood. In one embodiment, the biocompatible liquid further comprises a hemodiluent and the hemodiluent is administered separately from the oxygen carrier.
REFERENCES:
patent: 3482575 (1969-12-01), Claff et al.
patent: 3975512 (1976-08-01), Long
patent: 4073879 (1978-02-01), Long, Jr.
patent: 4275726 (1981-06-01), Schael
patent: 4301144 (1981-11-01), Iwashita et al.
patent: 4473494 (1984-09-01), Tye
patent: 4526715 (1985-07-01), Kothe et al.
patent: 4600531 (1986-07-01), Walder
patent: 4698387 (1987-10-01), Schmidt et al.
patent: 4777244 (1988-10-01), Bonhard et al.
patent: 4861867 (1989-08-01), Estep
patent: 4911929 (1990-03-01), Farmer et al.
patent: 4927623 (1990-05-01), Long, Jr.
patent: 4963130 (1990-10-01), Osterholm
patent: 4981691 (1991-01-01), Osterholm et al.
patent: 4987154 (1991-01-01), Long, Jr.
patent: 5080885 (1992-01-01), Long, Jr.
patent: 5130230 (1992-07-01), Segall et al.
Faithfull, N. S. et al., Peripheral vascular responses to fluorocarbon administration, Microvascular Research 33:183-193 (1987).
Faithfull, N. S. et al., Critical levels of O.sub.2 extraction following hemodilution with dextran of fluosol-DA. J of Critical Care 3(1): 14-18 (1988).
Federspiel, W. J. et al., A theoretical analysis of the effect of the particulate nature of blood on oxygen release in capillaries. Microvascular Research 32: 164-189 (1986).
Fukushima, K. et al., Clinical experience of hemodilution with fluosol-DA. Jpn. J. Anesthesiol. 30(7): 741-745 (with abstract & translation) (1981).
Giordano, G. F. et al., An autologous blood program coordinated by a regional blood center: a 5-year experience. Transfusion 31(6): 509-512 (1991).
Gould, S. A. et al., Fluosol-DA as a red-cell substitute in acute anemia. New Engl. J. Med. 314: 1653-1656 (1986).
Greenwalt, et al., Perioperative red blood cell transfusion. JAMA 260(18): 2700-2703 (1988).
Gutierrez, G., The rate of oxygen release and its effect on capillary O.sub.2 tension: a mathematical analysis. Respiration Physiology 63: 79-96 (1986).
Homer, L. D. et al., Oxygen gradients between red blood cells in the microcirculation. Microvascular Research 22: 308-323 (1981).
Mercuriali, F. et al., A safe alternative for surgical patients. Autologous Blood 2-30 (1991).
Messmer, K. et al., Present state of intentional hemodilution. Eur. surg. Res. 18: 254-263 (1986).
Messmer, K. et al., Oxygen supply to the tissues during limited normovolemic hemodilution. Res. exp. Med. 159: 152-166 (1973).
Riess, J. G., Overview of progress in the fluorocarbon approach to in vivo oxygen delivery. Biomat., Art. Cells & Immob. Biotech. 20(2-4): 183-202 (1992).
Riess, J. G. et al., Design, synthesis and evaluation of fluorocarbons and surfactants for in vivo applications new perfluoralkylated polyhydroxylated surfactants. Int'l Symposium on Blood Substitutes, Montreal (1987).
Riess, J. G., Reassessment of criteria for the selection of perfluorochemicals for second-generation blood substitutes: analysis of structure/property relationships. Artificial Organs 8(1): 44-56 (1984).
Riess, J. G., Fluorocarbon-based in vivo oxygen transport and delivery systems. Vox Sang 61: 225-239 (1991).
Sheffield, C. et al., Preparation and in vivo evaluation of two bovine hemoglobin-based plasma expanders. Biotechnol. Appl. Biochem. 12(6): 630-642 (1990).
Stehling, L. et al., Acute normovolemic hemodilution. Transfusion 31(9): 857-868 (1991).
Winslow, R. M., A model for red cell O.sub.2 uptake. International J. of Clinical Monitoring and Computing 2: 81-93 (1985).
Zauder, H. L., Preoperative hemoglobin requirements. Hemorrhagic Disorders 8(3): 471-480 (1990).
Zuck, T. F. et al., Autologous transfusion practice. Vox Sang 58: 234-253 (1990).
Faithfull Nicholas S.
Keipert Peter E.
Riess Jean G.
Roth Duane J.
Zuck Thomas F.
Alliance Pharmaceutical Corp.
Rimell Sam
LandOfFree
Facilitated oxygen delivery in conjunction with hemodilution does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Facilitated oxygen delivery in conjunction with hemodilution, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Facilitated oxygen delivery in conjunction with hemodilution will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1825254